This is a working overview of circular dichroism, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-11-28 and is reviewed periodically as new material appears.
质量控制环节关注外观、含量、纯度、有关物质、水分与微生物限度等项目。检测结果需要有对照品和系统适用性数据支持，单次测定不足以判定批次的稳定性。实验室之间方法转移时，色谱柱品牌与梯度差异常导致保留时间漂移，因此方法验证十分必要。
固体状态的 tirzepatide 通常以冻干粉形式保存，推荐在低温、避光、干燥条件下存放，常见区间为 2 至 8 摄氏度，长期保存可考虑更低温度并避免反复冻融。冻融循环会导致肽链聚集或析出，从而影响后续定量结果。容器密封性与湿度控制同样是稳定性研究中反复强调的因素。
溶解操作一般使用注射用水或适宜的水性缓冲液，必要时加入少量助溶剂以改善溶解速度，但应避免剧烈涡旋振荡，因为剪切力可能促进聚集。配制后的溶液在冷藏条件下的稳定时间通常短于固体形态，具体时限取决于浓度、缓冲体系与容器材质。是否加入防腐成分，则取决于用途是否为多次取样。
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
| Property | Value | Notes |
|---|---|---|
| 储存温度 | 2 至 8 摄氏度 | 固体粉末，避光密封 |
| 外观 | 白色至类白色冻干粉 | 溶解后为澄清至微乳光 |
| 溶解性 | 易溶于水性缓冲液 | 避免剧烈振荡 |
| 常规纯度方法 | 反相高效液相色谱 | 紫外或质谱检测 |
| 定量方法 | 液相色谱串联质谱 | 配合固相萃取前处理 |
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
Regulatory and quality discussions place the peptide within established guidance for synthetic peptides and biologics. Forced degradation studies, in which samples are exposed to heat, acid, base, peroxide, and light, identify likely degradation products and validate the selectivity of analytical methods. Reference standards allow comparison across laboratories and production batches. Purity specifications reported in the literature usually combine chromatographic purity with mass confirmation. Which impurity thresholds are meaningful for long-term behavior is still debated, and no single universal specification has been adopted across all jurisdictions.
Routine characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity assessment, usually with ultraviolet detection near 214 nanometers. Intact mass measurement by liquid chromatography coupled to mass spectrometry confirms molecular identity against a theoretical value. Sequence-level confirmation uses enzymatic digestion followed by tandem mass spectrometry, an approach known as peptide mapping. Amino acid analysis gives an independent check on composition. Circular dichroism spectra are used to estimate helical content in aqueous buffer.
Stability depends strongly on physical form. The dry powder is generally regarded as stable for extended periods when held at or below minus twenty degrees Celsius in a sealed, desiccated container. In solution, degradation pathways include deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation. Reaction rates for these pathways rise with temperature. Repeated freezing and thawing of solutions promotes aggregation, and light exposure can accelerate some oxidative changes. Buffer composition and pH influence which pathway dominates at a given temperature.
=== Culturing === Cheese is made by bringing milk (possibly pasteurised) in the cheese vat to a temperature required to promote the growth of the bacteria that feed on lactose and thus ferment the lactose into lactic acid. These bacteria in the milk may be wild, as is the case with unpasteurised milk, added from a culture, frozen or freeze dried concentrate of starter bacteria. Bacteria which produce only lactic acid during fermentation are homofermentative; those that also produce lactic acid and other compounds such as carbon dioxide, alcohol, aldehydes and ketones are heterofermentative. Fermentation using homofermentative bacteria is important in the production of cheeses such as Cheddar, where a clean, acid flavour is required. For cheeses such as Emmental, the use of heterofermentative bacteria is necessary to produce the compounds that give its characteristic fruity flavours and, importantly, the gas that results in the formation of bubbles in the cheese ('eye holes'). Starter cultures are chosen to give a cheese its specific characteristics. In the case of mould-ripened cheese such as Stilton, Roquefort or Camembert, mould spores (fungal spores) may be added to the milk in the cheese vat or can be added later to the cheese curd.
A Bitubale is baled asphalt, in cold form, wrapped in white plastic or in asphalt-based film. Invented by Singapore-based Eastern Petroleum Group, Bitubale is a green technology innovation for the global bitumen (asphalt) transport supply chain. Bitubales are produced in specially designed plants for cooling, dispensing, encapsulation, and packing of bitumen at its supply source. The technologies support cold-form transport of bitumen with zero waste at the end of its supply chain. Primary benefits of the Bitubale, over hot-form transported asphalt, are halving of the CO2 emissions across the bitumen transport supply chain, large increases in workplace safety for bitumen/asphalt transport workers, elimination of long-term health risks from bitumen/asphalt fumes for transportation workers, elimination of accidental pollution of environmental assets during asphalt transport, and elimination of polluting bitumen-residue waste in millions of discarded drums in landfills.
=== Mechanism === ERAP1 uses a catalytic mechanism similar to the one proposed for LTA4 hydrolase. ERAP1 adopts a thermolysinlike fold and has been crystallized in two distinct conformations: a. the open and b. the closed (Figure 2). In the open conformation, domain IV lies away from the active site thus making the internal cavity more accessible to substrates. In the closed conformation, the internal cavity is occluded from the external solvent, and it is of adequate size to accommodate a 16-residue peptide. The catalytic residues and in particular Tyr438 are optimally positioned for catalysis in the closed conformation. Consequently, substrate binding is hypothesized to take place in the open conformation, while N-terminal bond cleavage takes place in the closed one. It has been proposed that binding of substrate or small inhibitors induces conformational closing of ERAP1 in solution. ERAP1 prefers peptide substrates 9-16 amino acids long and is much less active for peptides 8-9 amino acids long. It is considered that ERAP1 uses a "molecular ruler" mechanism, according to which the substrate binds through its hydrophobic C-terminus in a hydrophobic pocket at the junction of domain III and domain IV and the N-terminus binds to the active site. When the length of the peptide is shorter than 8 or 9 amino acids, the peptide is too short to reach the active site, limiting rates of cleavage. ERAP1 has a wide substrate specificity with a preference for hydrophobic residues (e.g. leucine and methionine) at the N-terminus of the peptide substrate.
== Other uses == Gender and sexual diversity Gibraltar Social Democrats, a political party in Gibraltar Go Skateboarding Day General sewing data or garment sewing data, in a predetermined motion time system Great Sun of Discovery, in the dating system used by the Improved Order of Red Men Government shutdown Get Stuff Done
=== Reign of Doomsday === Boodikka later appears at the remains of the destroyed planet New Krypton, where she encounters Batman and Supergirl. Boodikka explains that the Guardians had sent her on a mission to survey the ruins as a follow-up to the Green Lantern Corps' initial inspection of the planet. Suddenly, the heroes are attacked by Doomsday, who strikes Boodikka before she can react. Due to her injuries, Boodikka is unable to effectively wield her ring and is nearly captured by Doomsday before being rescued by Supergirl. With Starman and Saint Walker acting as a distraction, Batman and Supergirl take Boodikka to the JLA Watchtower. Doomsday follows the two aboard. As he's about to attack them, Cyborg Superman emerges from Boodikka's body. After Doomsday captures Supergirl and Cyborg Superman and flees the Watchtower, Starman states that Boodikka is healing herself in the Justice League's medical facility and should soon have enough energy to return to Oa. In War of the Green Lanterns, Boodikka and the Alpha Lanterns are killed by Alpha Lantern Varix and buried on Oa.
Sources: en.wikipedia.org
N-Acetylputrescine (NacPut), also known as monoacetylputrescine, is an endogenous metabolite of putrescine and a precursor and metabolic intermediate in the biosynthesis of γ-aminobutyric acid (GABA) from putrescine. The metabolic pathway is specifically putrescine into N-acetylputrescine by putrescine acetyltransferase (PAT), N-acetylputrescine into N-acetyl-γ-aminobutyraldehyde (N-acetyl-GABAL or N-acetyl-GABA aldehyde) by monoamine oxidase B (MAO-B), N-acetyl-GABAL into N-acetyl-γ-aminobutyric acid (N-acetyl-GABA) by aldehyde dehydrogenase (ALDH), and N-acetyl-GABA into GABA by an unknown deacetylase enzyme. This pathway is a minor alternative pathway to the major and primary pathway in which GABA is synthesized from glutamate. There is also another alternative pathway in which putrescine is converted into GABA with γ-aminobutyraldehyde (GABAL or GABA aldehyde) as an intermediate instead. It has been estimated that about 2 to 3% of GABA is synthesized from putrescine in the mouse brain, whereas in the case of the rat brain, the amount was negligible. In 2021, it was discovered that MAO-B does not mediate dopamine catabolism in the rodent striatum but instead participates in striatal GABA synthesis and that synthesized GABA in turn inhibits dopaminergic neurons in this brain area. It has been found that MAO-B, via the putrescine pathway, importantly mediates GABA synthesis in astrocytes in various brain areas, including in the hippocampus, cerebellum, striatum, cerebral cortex, and substantia nigra pars compacta (SNpc).
Cocaine has a short elimination half-life of 0.7–1.5 hours and is extensively metabolized by plasma esterases and also by liver cholinesterases, with only about 1% excreted unchanged in the urine. The metabolism is dominated by hydrolytic ester cleavage, so the eliminated metabolites consist mostly of benzoylecgonine (BE), the major metabolite, and other metabolites in lesser amounts such as ecgonine methyl ester (EME) and ecgonine. Further minor metabolites of cocaine include norcocaine, p-hydroxycocaine, m-hydroxycocaine, p-hydroxybenzoylecgonine (pOHBE), and m-hydroxybenzoylecgonine. Depending on liver and kidney functions, cocaine metabolites are detectable in urine between three and eight days. Generally speaking benzoylecgonine is eliminated from someone's urine between three and five days. In urine from heavy cocaine users, benzoylecgonine can be detected within four hours after intake and in concentrations greater than 150 ng/mL for up to eight days later.
Brazil: The leaf juice is taken orally to induce vomiting and narcosis. Colombia: Fresh leaf is used as poultice over boils and infected wounds; the leaves are crushed with oil from palms and used as hair treatment to prevent baldness. Cuba: Extract of the leaf is taken orally to treat dysmenorrhea. East Africa: Dried leaves of Nicotiana tabacum and Securinega virosa are mixed into a paste and used externally to destroy worms in sores. Ecuador: Leaf juice is used for indisposition, chills and snake bites and to treat pulmonary ailments. Fiji: Fresh root is taken orally for asthma and indigestion; fresh root is applied ophthalmically as drops for bloodshot eyes and other problems; seed is taken orally for rheumatism and to treat hoarseness. Guatemala: Leaves are applied externally by adults for myiasis, headache and wounds; hot water extract of the dried leaf is applied externally for ring worms, fungal diseases of the n, wounds, ulcers, bruises, sores, mouth lesions, stomatitis and mucosa; leaf is orally taken for kidney diseases. Haiti: Decoction of dried leaf is taken orally for bronchitis and pneumonia. Hong Kong: Fresh leaves are mashed and combined with vegetable oil to create a potion that is applied to injuries for it to heal faster. This practice is also apparent in other places in China. Iran: Infusion of the dried leaf is applied externally as an insect repellent; ointments made from crushed leaves are used for baldness, dermatitis and infectious ulceration and as a pediculicide.
== History == MMDA was first synthesized and studied by Gordon Alles at the Edgewood Arsenal in the mid-1950s. Its Edgewood Arsenal code name is unknown. Subsequently, Alexander Shulgin synthesized MMDA in 1962 and discovered its psychoactive effects that same year. Shulgin published his findings on MMDA in the scientific literature in 1964. Use of MMDA in psychedelic-assisted psychotherapy was studied by Shulgin, Thornton Sargent, and Claudio Naranjo in the mid-1960s and their findings were published in 1973. Naranjo also described MMDA for these purposes in his 1973 book The Healing Journey: New Approaches to Consciousness. Shulgin subsequently further described MMDA in his book PiHKAL (Phenethylamines I Have Known and Loved) in 1991.
=== Pharmacodynamics === Suvorexant acts as a selective dual antagonist of the orexin (hypocretin) receptors OX1 and OX2. These receptors are the biological targets of the endogenous wakefulness-promoting orexin neuropeptides orexin-A and orexin-B. The binding affinities (Ki) of suvorexant at the human orexin receptors are 0.55 nM for the OX1 receptor and 0.35 nM for the OX2 receptor. The antagonistic potencies or functional inhibition (Kb) of suvorexant at the human orexin receptors are 65 nM for the OX1 receptor and 41 nM for the OX2 receptor. Hence, suvorexant shows similar affinities and antagonistic activities at the OX1 and OX2 receptors in vitro. Suvorexant is highly selective for the orexin receptors over a large number of other targets (170 screened off-target receptors, enzymes, and transporters). In contrast to certain other sedatives and hypnotics, suvorexant is not a benzodiazepine or Z-drug and does not interact with GABA receptors.
Sources: en.wikipedia.org
== History == Ivar Bang first described the DBS as an unusual sampling method in 1913. The concept that capillary blood, obtained from pricking the heel or finger and blotted onto filter paper, could be used to screen for metabolic diseases in large populations of neonates was introduced in Scotland by Robert Guthrie in 1963. Neonatal screening for phenylketonuria became nationwide in 1969–70. Since then, Guthrie card samples have been collected routinely from infants in over 20 countries to screen for phenylketonuria and more recently for congenital hypothyroidism, sickle cell disorders and HIV infection. The limitations of sensitivity and specificity when screening such small volumes of blood restricted the use of dried blood spots for many years. However, recent advances such as the production of monoclonal antibodies, expression of synthetic proteins, and the introduction of the polymerase chain reaction have overcome many of these problems. This type of blood testing is now available for use at home by consumers in the U.S. Available blood tests include vitamin D, estrogen, testosterone, cortisol, TSH and lipids. New York is the only state that prohibits home blood spot testing.
The process required pressing tungsten powder into bars, then several steps of sintering, swaging, and then wire drawing. It was found that very pure tungsten formed filaments that sagged in use, and that a very small "doping" treatment with potassium, silicon, and aluminum oxides at the level of a few hundred parts per million (so-called AKS tungsten) greatly improved the life and durability of the tungsten filaments. The predominant mechanism for failure in tungsten filaments even now is grain boundary sliding accommodated by diffusional creep. During operation, the tungsten wire is stressed under the load of its own weight and because of the diffusion that can occur at high temperatures, grains begin to rotate and slide. This stress, because of variations in the filament, causes the filament to sag nonuniformly, which ultimately introduces further torque on the filament. It is this sagging that inevitably results in a rupture of the filament, rendering the incandescent lightbulb useless.
== Genetics == The gene encoding the enzyme is referred to as DDC is located on chromosome 7 in humans. It consists of 15 exons encoding a protein of 480 amino acids. Single nucleotide polymorphisms and other gene variations have been investigated in relation to neuropsychiatric disorders, for example, a one-base pair deletion at 601 and a four-base pair deletion at 722–725 in exon 1 in relation to bipolar disorder and autism. No direct correlation between gene variation and autism was found. More than 50 mutations of DDC have been correlated with AADC deficiency. This condition is most prevalent in Asia, presumably due to the founder effect. Alternative splicing events and promoters have been observed that lead to various forms of the AADC enzyme. Unique usage of certain promoters leads to transcription of only the first exon to produce an extra-neuronal isoform, and splicing of exon 3 leads to a product devoid of enzymatic activity. Analyses via porcine specimens have elucidated two AADC isoforms – resulting from exclusion of exon 5 and exons 5 and 6 – that lack a portion of the decarboxylating domain.
It was a formidable fighting force consisting of 1,487 tanks, 1,384 infantry fighting vehicles, 568 artillery pieces, 132 MLRS, 8 missile launchers, and 242 attack helicopters. It had a total troop strength of 146,321 troops. Its primary full strength fighting formations were the 1st Armored Division (United States), the 3rd Armored Division (United States) and the 1st Infantry Division (United States). The 2nd Armored Division (Forward) was assigned to the 1st Infantry Division as its third maneuver brigade. Its Task Force 1-41 Infantry would be the spearhead of VII Corps. In addition, the corps had the 2nd Cavalry Regiment (United States) to act as a scouting and screening force, and two further heavy divisions, the 1st Cavalry Division (United States) and the United Kingdom's 1st Armoured Division, as well as the U.S. 11th Aviation Group. VII Corps fought a number of large battles against Iraqi forces, with some of historic scope and size. Three of the battles at Norfolk, Medina Ridge, and 73 Easting are considered among the largest tank battles in history. By the end of combat operations on 28 February 1991, U.S. VII Corps had driven 260 kilometres (160 mi), captured 22,000 Iraqi soldiers, and destroyed 1,350 Iraqi tanks, 1,224 armored personnel carriers, 285 artillery pieces, 105 air defense systems, and 1,229 trucks.
Relamorelin (INN, USAN) (developmental code names RM-131, BIM-28131, BIM-28163) is a synthetic peptide, centrally penetrant, selective agonist of the ghrelin/growth hormone secretagogue receptor (GHSR) which is under development by Allergan pharmaceuticals for the treatment of diabetic gastroparesis, chronic idiopathic constipation, and anorexia nervosa. It is a pentapeptide and an analogue of ghrelin with improved potency and pharmacokinetics. In humans, relamorelin produces increases in plasma growth hormone, prolactin, and cortisol levels, and, like other GHSR agonists, increases appetite. As of June 2015, relamorelin is in phase II clinical trials for diabetic gastroparesis and constipation. The United States Food and Drug Administration (FDA) has granted Fast Track designation to relamorelin for diabetic gastroparesis. The development of the drug is uncertain as the most recent mention of it was in a 2019 SEC filing from the drug manufacturer lists the drug's expected launch year as 2024, but not in subsequent filings or press releases.
Sources: en.wikipedia.org
建议在低温、避光、干燥环境中密封保存，常见条件为 2 至 8 摄氏度，长期存放可置于更低温度。应避免反复冻融，并尽量减少容器开启次数。
溶解后的稳定时间通常短于固体形态，受浓度、缓冲液和容器材质影响。冷藏条件下一般只能维持较短时间，具体期限应通过实际稳定性实验确认。
反相高效液相色谱用于纯度与含量测定，液相色谱串联质谱用于生物基质中的定量，体积排阻色谱用于检测聚集体。多种方法结合才能较完整地表征样品。
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.